Clinical Trial Update: Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

Valemetostat tosylate (DS-3201b) Phase 2 study in relapsed or refractory Adult T-cell Leukemia/Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Leukemia Lymphoma

Drugs mentioned

• Valemetostat Tosylate (DS-3201b) (valemetostat tosylate)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Adult T-cell Leukemia/Lymphoma | Phase 2 | Status: COMPLETED